XTL BIopharmaceuticals Limited (XTLB) Company Profile


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

XTL BIopharmaceuticals Limited Company Snapshot

Business Description:

XTL BIopharmaceuticals Limited operates in the Pharmaceutical preparations sector. XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, for the treatment of multiple myeloma (MM) and hepatitis C. The Company's lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL's second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company. In November 2011, it acquired MinoGuard.

Stock Performance Chart for XTL BIopharmaceuticals Limited

Stock Data:

Recent Stock Performance:

Current Price (2/2/2012): .57
(Figures in Israel Shekels)

1 Week	3.3%	13 Weeks	4.6%

4 Weeks	8.6%	52 Weeks	-6.7%

XTL BIopharmaceuticals Limited Key Data:

Ticker:	XTLB	Country:	ISRAEL

Exchanges:	OTH	Major Industry:	Drugs, Cosmetics & Health Care

		Sub Industry:	Ethical Drug Manufacturers

2008 Sales	21,166,655 (Year Ending Jan 2009).	Employees:	8

Currency:	Israel Shekels	Market Cap:	116,297,984

Fiscal Yr Ends:	December	Shares Outstanding:	204,031,550

Share Type:	Ordinary	Closely Held Shares:	4,244,265

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.